Medcura, Inc.

Medcura, Inc. specializes in antimicrobial wound hydrogel dressings. These products are formulated for topical application to minor cuts and abrasions, aiming to support wound healing and lower infection risk. Examples include single-use sachets like the CutCure Sachet (0.068 fl oz) and tubes like the CutCure Tube (0.3 fl oz). The focus is on acute skin injuries, where these dressings provide localized treatment.

Medcura, Inc. is headquartered in the United States. Since its devices fall under U.S. regulatory jurisdiction, the company must comply with applicable U.S. requirements for medical device authorization. The location ensures alignment with FDA guidelines, including classification, listing, and post-market obligations for Class II devices.

Medcura’s wound hydrogel dressings are classified as Class II under U.S. regulations. This classification indicates moderate risk and requires compliance with specific controls, such as performance standards or post-market surveillance, to ensure safety and effectiveness. Class II designation also mandates listing in the FDA’s Unique Device Identifier (UDI) database, which helps track and monitor these products in the market.

Yes, Medcura’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This inclusion means the products have been assigned a standardized identifier for traceability, reducing errors in ordering, inventory, and recall management. For users, it ensures transparency and easier verification of device authenticity and compliance with U.S. regulatory requirements.